Phase III Clinical Trial for Assessment of Efficacy and Safety of DA-3002 (Recombinant Human Growth Hormone) in Patients With Turner's Syndrome
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 22 Sep 2017
At a glance
- Drugs Somatrogon (Primary)
- Indications Turner's syndrome
- Focus Registrational; Therapeutic Use
- Sponsors Dong-A ST
- 19 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 19 Sep 2017 Planned primary completion date changed from 1 Jun 2016 to 1 May 2018.
- 16 Jun 2014 New trial record